Scarica l'app Stockscreener
0.8398
4.27%
0.0344
Dopo l'orario di chiusura:
.84
0.0002
+0.02%
Precedente Chiudi:
$0.8054
Aprire:
$0.7951
Volume 24 ore:
1.06M
Relative Volume:
0.90
Capitalizzazione di mercato:
$83.75M
Reddito:
$1.63M
Utile/perdita netta:
$-40.95M
Rapporto P/E:
-1.4309
EPS:
-0.5869
Flusso di cassa netto:
$-18.80M
1 W Prestazione:
-22.24%
1M Prestazione:
-38.25%
6M Prestazione:
+66.30%
1 anno Prestazione:
-39.58%
Intervallo 1D:
$0.7609
$0.8695
Intervallo di 1 settimana:
$0.68
$1.06
Portata 52W:
$0.387
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Nome
Rani Therapeutics Holdings Inc
Settore
Industria
Telefono
(408) 457-3700
Indirizzo
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.8398 | 83.75M | 1.63M | -40.95M | -18.80M | -0.5869 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-02 | Iniziato | Oppenheimer | Outperform |
| 2024-06-14 | Iniziato | Maxim Group | Buy |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-07-27 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-13 | Iniziato | Wedbush | Outperform |
Mostra tutto
Rani Therapeutics Holdings Inc Borsa (RANI) Ultime notizie
RANI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Canaccord Genuity Group Lowers Rani Therapeutics (NASDAQ:RANI) Price Target to $5.00 - MarketBeat
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Market Review: Can Rani Therapeutics Holdings Inc reach all time highs this yearSwing Trade & Safe Entry Zone Tips - baoquankhu1.vn
Can Rani Therapeutics Holdings Inc beat the S P 5002026 Weekly Recap & Community Consensus Trade Alerts - baoquankhu1.vn
Loss Report: Is Rani Therapeutics Holdings Inc likely to announce a buybackMarket Risk Summary & High Conviction Buy Zone Picks - baoquankhu1.vn
Equities Analysts Offer Predictions for RANI Q1 Earnings - MarketBeat
Rani Therapeutics Holdings (RANI) price target decreased by 13.51% to 8.16 - MSN
Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In Growth - Yahoo Finance
Rani Therapeutics | 3: Initial statement of beneficial ownership of securities- Javadi Alireza - Moomoo
Rani Therapeutics (RANI) CTO discloses initial stock, RSU and option holdings - stocktitan.net
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Vanguard disaggregates holdings; reports 0 RANI shares (RANI) - Stock Titan
Rani Therapeutics (NASDAQ:RANI) Given "Buy" Rating at HC Wainwright - MarketBeat
Rani Therapeutics 2025 Annual Report: Oral Biologics Pipeline, Clinical Updates, and Risk Factors 535657 - Minichart
Earnings Call Summary | Rani Therapeutics(RANI.US) Q4 2025 Earnings Conference - news.futunn.com
Earnings call transcript: Rani Therapeutics Q4 2025 sees improved liquidity but misses EPS forecast - au.investing.com
Earnings call transcript: Rani Therapeutics Q4 2025 sees improved liquidity but misses EPS forecast By Investing.com - Investing.com South Africa
Rani Therapeutics Q4 Earnings Call Highlights - MarketBeat
Rani Therapeutics Holdings Inc reports results for the quarter ended September 30Earnings Summary - TradingView
RANI: Major Chugai deal, RT-114 clinical progress, and strengthened finances mark a transformative 2025 - TradingView
RANI: Advanced pipeline, secured major Chugai deal, and extended cash runway into Q4 2027 - TradingView
Rani Therapeutics 2025 10-K: $1.63M revenue, $(0.45) EPS - TradingView
RANI: Net loss improved to $41.0M in 2025, with $49.7M cash and strengthened by a $60.3M private placement - TradingView
Rani Therapeutics (NASDAQ: RANI) boosts cash, advances oral biologics pipeline - Stock Titan
Rani Therapeutics (NASDAQ:RANI) Announces Quarterly Earnings Results - MarketBeat
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update - The Manila Times
[8-K] Rani Therapeutics Holdings, Inc. Reports Material Event - Stock Titan
Rani Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Rani Therapeutics Appoints Jesper Hoiland as Head of Strategy to Advance Corporate and Pipeline Prioritization - Bitget
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization - The Manila Times
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Drive Corporate and Pipeline Development - quiverquant.com
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization - GlobeNewswire Inc.
Rani Therapeutics Holdings Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
RANI Stock Price, Quote & Chart | RANI THERAPEUTICS HOLDINGS-A (NASDAQ:RANI) - ChartMill
Rani Therapeutics (RANI) Expected to Announce Earnings on Monday - MarketBeat
If You Invested $1,000 in Rani Therapeutics Holdings, Inc. (RANI) - Stock Titan
US Market Recap: Will Rani Therapeutics Holdings Inc outperform during market ralliesFed Meeting & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Analyst Calls: Will Rani Therapeutics Holdings Inc outperform during market ralliesTrade Risk Assessment & Real-Time Stock Entry Alerts - baoquankhu1.vn
Volatility Watch: Can Rani Therapeutics Holdings Inc beat the S P 5002026 Review & Risk Managed Investment Entry Signals - baoquankhu1.vn
Published on: 2026-03-21 04:57:56 - baoquankhu1.vn
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Rani Therapeutics Holdings Inc (RANI) - MSN
Aug Momentum: Can Rani Therapeutics Holdings Inc navigate macro headwinds2026 Growth vs Value & AI Driven Stock Reports - baoquankhu1.vn
RANI SEC FilingsRani Therapeutics Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Rani Therapeutics Holdings Inc. (RANI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Rani Therapeutics Hldgs (RANI) Stock Analysis Report | Financials & Insights - Benzinga Japan
US Market Wrap: Will Rani Therapeutics Holdings Inc outperform during market rallies2026 Institutional Moves & High Win Rate Trade Tips - baoquankhu1.vn
What is the next catalyst for Rani Therapeutics Holdings Inc2026 Market WrapUp & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Rani Therapeutics Holdings Inc Azioni (RANI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):